BANGKOK GENOMICS INNOVATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.82 THB | +2.17% |
|
-3.42% | 0.00% |
Valuation
| Fiscal Period: December | 2024 |
|---|---|
| Capitalization 1 | 1,692 |
| Enterprise Value (EV) 1 | 1,692 |
| P/E ratio | - |
| Yield | 1.42% |
| Capitalization / Revenue | - |
| EV / Revenue | - |
| EV / EBITDA | - |
| EV / FCF | - |
| FCF Yield | - |
| Price to Book | 2.27 x |
| Nbr of stocks (in thousands) | 600,000 |
| Reference price 2 | 2.820 |
| Announcement Date | - |
1THB in Million2THB
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2023 | 2024 |
|---|---|---|
| Net sales | - | - |
| EBITDA | - | - |
| EBIT | - | - |
| Operating Margin | - | - |
| Earnings before Tax (EBT) | - | - |
| Net income | 32.14 | - |
| Net margin | - | - |
| EPS | 0.0700 | - |
| Free Cash Flow | - | - |
| FCF margin | - | - |
| FCF Conversion (EBITDA) | - | - |
| FCF Conversion (Net income) | - | - |
| Dividend per Share 1 | - | 0.0400 |
| Announcement Date | 19/03/24 | - |
1THB
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2023 | 2024 |
|---|---|---|
| Net Debt | - | - |
| Net Cash position | - | - |
| Leverage (Debt/EBITDA) | - | - |
| Free Cash Flow | - | - |
| ROE (net income / shareholders' equity) | - | - |
| ROA (Net income/ Total Assets) | - | - |
| Assets | - | - |
| Book Value Per Share 1 | - | 1.240 |
| Cash Flow per Share | - | - |
| Capex | - | - |
| Capex / Sales | - | - |
| Announcement Date | 19/03/24 | - |
1THB
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 45.98M | |
| +51.85% | 57.87B | |
| +41.42% | 40.25B | |
| -5.25% | 39.94B | |
| -5.16% | 28.54B | |
| +12.79% | 26.4B | |
| -20.18% | 19.33B | |
| +30.88% | 12.4B | |
| +0.61% | 12.23B | |
| +25.06% | 12.2B |
- Stock Market
- Equities
- BKGI Stock
- Financials Bangkok Genomics Innovation
